In utero exposure to breast cancer treatment: a population-based perinatal outcome study
Menée en Australie et en Nouvelle-Zélande, cette étude de cohorte prospective analyse l'état de santé des bébés exposés in utero à de la chimiothérapie dispensée chez des patientes atteintes d'un cancer du sein diagnostiqué pendant la grossesse, ainsi que les caractéristiques périnatales (naissance avant terme, par césarienne,etc.)
Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks’ gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.